New Products and Industry News
- 0 Comments
- 2600 reads
This agreement means approximately 7.5 million people now have access to a proven treatment option for DFUs.
Graftjacket RTM is indicated for the repair or replacement of damaged or inadequate integumental tissue, such as diabetic ulcers, or for other homologous uses of human integument. Proprietary processing allows the body to accept Graftjacket RTM and reduces the potential for a rejection response. Graftjacket RTM provides immediate coverage to the wound, and is readily repopulated with the patient’s own cells and revascularized by the body. Ultimately, Graftjacket RTM acts as a scaffold that allows the body to convert the matrix to functional host tissue in ulcer repair.
Visit www.kci1.com for more information.